Ashwani Verma, an analyst from UBS, maintained the Buy rating on Insmed. The associated price target is $194.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ashwani Verma has given his Buy rating due to a combination of factors that highlight Insmed’s promising growth prospects. The launch of Brinsupri for NCFB is expected to see strong initial uptake, supported by the company’s proactive engagement with healthcare professionals and a significant number of identified patients. This positions Insmed well to capitalize on a potential blockbuster opportunity, with projected peak sales significantly exceeding consensus estimates.
Furthermore, Verma sees additional upside from Brinsupri’s potential in CRSsNP and the commercial opportunity for TPIP in IPF. The anticipated Phase 2b data for Brinsupri in CRSsNP and the Phase 3 trial design for TPIP in IPF could serve as important catalysts, with both having a substantial probability of success. These developments, alongside the strategic deployment of Insmed’s sales force and favorable efficacy comparisons, underpin Verma’s optimistic outlook for the company’s future performance.
In another report released yesterday, Evercore ISI also maintained a Buy rating on the stock with a $180.00 price target.